Vor Bio (VOR) announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg. The data, which was presented in a poster at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 8th, demonstrated durable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of improved relapse free survival compared to published high-risk AML comparators. The data released today included 25 patients treated with trem-cel of which 15 had received Mylotarg as of the data cut-off date of November 1, 2024. The data demonstrated: Preliminary evidence of improved relapse-free survival compared to published groups of AML patients at high risk of relapse post hematopoietic stem cell transplant. Shielding of the blood system, with maintained neutrophil and platelet counts across multiple Mylotarg doses of 0.5, 1, and 2 mg/m2. Broadened therapeutic index for Mylotarg when administered after trem-cel. Reliable engraftment, with 100% of patients achieving primary neutrophil engraftment, robust platelet recovery, and full myeloid donor chimerism at Day 28. Trem-cel continues to be manufactured with high CD33 editing efficiency
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VOR:
- Vor Bio price target lowered to $8 from $10 at Oppenheimer
- Vor Bio price target lowered to $14 from $22 at Baird
- Vor Biopharma Reports Q3 2024 Financial Results
- Vor Bio reports Q3 EPS (40c), consensus (40c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
